GHK-Cu + KPV Blend 50mg / 20mg

GHK-Cu 50 mg / KPV 20 mg is a high-purity dual-peptide research preparation containing 50 mg GHK-Cu and 20 mg KPV, supplied exclusively for scientific investigation and controlled laboratory experimentation.

For research use only — not for human or veterinary use.

 

Product Overview

GHK-Cu 50 mg / KPV 20 mg is a dual-peptide research preparation combining two distinct peptide compounds within a single lyophilized research vial.

GHK-Cu is a copper-binding tripeptide widely investigated within peptide chemistry, molecular signalling and cellular research models, while KPV is a short tripeptide studied in experimental systems involving peptide-mediated signalling and biochemical regulatory pathways.

This research preparation contains 50 mg GHK-Cu together with 20 mg KPV, providing researchers with a combined peptide material for controlled laboratory investigation.

Independent third-party laboratory analysis confirmed greater than 99.8 percent purity for GHK-Cu and 99.3 percent purity for KPV.

Identity was further evaluated through retention time analysis and mass spectrometry, with molecular ion masses identified at 341 Da for GHK-Cu and 342 Da for KPV.

Microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count, while bacterial endotoxin analysis returned a result of 0.005 EU/mg.

Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm.

These independently generated analytical results provide detailed batch-specific documentation for this GHK-Cu 50 mg / KPV 20 mg research preparation.

 

Peptide Overview

GHK-Cu and KPV are structurally distinct tripeptides investigated across different areas of experimental peptide and molecular research.

GHK-Cu consists of the peptide sequence glycyl-L-histidyl-L-lysine associated with copper, creating a copper-binding peptide complex frequently examined within biochemical and cellular research systems.

KPV is a short peptide consisting of the amino acid sequence lysine-proline-valine and is investigated within controlled laboratory models involving peptide signalling and molecular regulatory mechanisms.

The combination of 50 mg GHK-Cu and 20 mg KPV allows researchers to investigate both peptide structures within the same controlled experimental preparation.

Each peptide component was independently characterised by Liquilabs using peptide screening, retention time analysis and mass spectrometry.

 

Historical Background and Scientific Context

Short-chain peptides and peptide-metal complexes have become increasingly important research materials within modern peptide chemistry, molecular biology and biochemical investigation.

Advances in peptide synthesis and analytical instrumentation now allow individual peptide components within combined research preparations to be characterised independently.

Chromatographic techniques can assess assay content and purity for individual compounds, while retention time analysis and mass spectrometry provide additional information regarding molecular identity.

Microbiological analysis, bacterial endotoxin testing and elemental impurity screening further contribute to the analytical characterisation of lyophilized peptide research materials.

GHK-Cu 50 mg / KPV 20 mg represents a dual-peptide preparation in which both peptide components have been independently characterised within the same production batch.

 

Mechanistic Focus in Research

Within controlled laboratory environments, GHK-Cu and KPV may be investigated in relation to peptide chemistry, molecular interactions and cellular signalling mechanisms.

Research investigations may explore:

• Peptide-mediated cellular signalling
• Copper-peptide complex research
• Short-chain peptide interactions
• Cellular response mechanisms
• Molecular communication pathways
• Biochemical regulatory systems
• Comparative peptide investigations
• Combined peptide research models
• Controlled in vitro laboratory studies

These research areas relate exclusively to experimental laboratory investigation and do not imply diagnostic, therapeutic or clinical applications.

 

Analytical Verification (COA)

Each Grail Formula production batch is supported by independent analytical documentation designed to provide transparent batch-specific information regarding the research material supplied.

Analytical testing for this GHK-Cu 50 mg / KPV 20 mg production batch was performed by Liquilabs s.r.o. Czechia.

Batch: GF-GHKKPV-B241

• GHK-Cu Content: 50 mg
• GHK-Cu Purity: greater than 99.8 %
• GHK-Cu Identification by Retention Time: 0.994
• GHK-Cu Molecular Ion Mass: 341 Da
• KPV Content: 20 mg
• KPV Purity: 99.3 %
• KPV Identification by Retention Time: 0.996
• KPV Molecular Ion Mass: 342 Da
• Bacterial Endotoxins: 0.005 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening confirmed a GHK-Cu assay result of 47.9 mg for the 50 mg component and a KPV assay result of 19.5 mg for the 20 mg component.

Purity analysis returned greater than 99.8 percent for GHK-Cu and 99.3 percent for KPV.

Retention time identity analysis returned 0.994 for GHK-Cu and 0.996 for KPV.

Mass spectrometry identified molecular ion masses of 341 Da for GHK-Cu and 342 Da for KPV.

Bacterial endotoxin testing returned a result of 0.005 EU/mg, remaining within the laboratory’s stated acceptable range of 0–0.5 EU/mg.

Microbiological testing reported 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count.

Elemental impurity screening reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm.

Together, these analytical procedures provide independent batch-specific characterisation of the GHK-Cu 50 mg / KPV 20 mg research preparation.

 

Research Applications

Within controlled laboratory environments, GHK-Cu 50 mg / KPV 20 mg may be utilised in experimental models designed to investigate peptide biology, molecular signalling and biochemical interactions.

Examples of research applications include:

• GHK-Cu peptide-complex investigations
• KPV peptide research
• Combined peptide interaction studies
• Peptide-mediated signalling research
• Cellular response investigations
• Molecular pathway analysis
• Comparative peptide studies
• Controlled in vitro laboratory research

These applications are intended exclusively for scientific and laboratory investigation.

 

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification designed to provide transparent and traceable batch-specific documentation.

For this GHK-Cu 50 mg / KPV 20 mg production batch, independent laboratory testing included:

• Individual assay determination for GHK-Cu and KPV
• Individual purity assessment for both peptide components
• Retention time identity verification
• Molecular ion mass identification
• Bacterial endotoxin analysis
• Total aerobic microbial count
• Total yeast and mold count
• Comprehensive elemental impurity screening
• Complete batch-specific traceability

Independent laboratory analysis provides researchers with analytical information relating directly to the tested production batch rather than relying solely on general product specifications.

This approach supports analytical transparency, batch traceability and consistency across Grail Formula research compounds.

 

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently analysed research compounds supported by detailed Certificates of Analysis and transparent batch-specific laboratory documentation.

For GHK-Cu 50 mg / KPV 20 mg batch GF-GHKKPV-B241, independent analysis was performed by Liquilabs s.r.o. Czechia and the Certificate of Analysis was published on 15 August 2026.

Both peptide components were independently evaluated for assay content, purity, retention time identity and molecular ion mass.

The analytical programme additionally included bacterial endotoxin testing, microbiological analysis and comprehensive elemental impurity screening.

This multi-method analytical approach provides researchers with extensive independent information regarding both peptide components within the tested research preparation.

 

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Contains 50 mg GHK-Cu and 20 mg KPV
• GHK-Cu purity greater than 99.8 %
• KPV purity confirmed at 99.3 %
• Identity verified by retention time analysis
• Molecular ion mass identified at 341 Da for GHK-Cu
• Molecular ion mass identified at 342 Da for KPV
• Bacterial endotoxin level of 0.005 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mold count: 0 CFU/g
• Seven tested elemental impurities below 0.001 ppm
• Complete batch-specific COA traceability
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.